Background: Previous clinical and animal studies suggested that medium-chain triglycerides (MCT) might be an alternative energy substrate for the brain and might benefit patients with Alzheimer's disease (AD), but the clinical evidence is not substantial or totally convincing.
Objective: To investigate the effects of MCT on cognitive ability in patients with mild to moderate AD and explore the changes in peripheral blood metabolomics.
Methods: A double-blind, randomized, placebo-controlled crossover study was undertaken in 53 mild to moderate AD patients. Participants were randomized between two sequences (placebo followed by MCT or MCT followed by placebo) and took MCT jelly or placebo jelly (canola oil) by mouth three times daily (total daily fat dose: 17.3 g MCT, or 19.7 g canola oil) for 30 days per phase. The primary outcome was cognition as measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale, Chinese version (ADAS-Cog-C). The secondary outcome was self-care as measured by the activities of daily living scale (ADL) and changes in plasma metabolites.
Results: This study showed a significant (p < 0.01) reduction in ADAS-Cog-C scores between the MCT (2.62 points below baseline) and placebo interventions (2.57 points above baseline). Data from 46 (86.8%) APOE4 subjects who completed the entire study were analyzed. Changes in ADL scores were not significantly different between the MCT and placebo interventions (p > 0.05). The concentrations of TC, HDL-C, β-hydroxybutyrate and acetoacetate were significantly higher in the MCT group than in the placebo group (p < 0.05). Lysophosphatidylcholine 16:0 (LysoPC (16:0)), LysoPC (P-18:0), LysoPC (P-18:1(9Z)), LysoPC (20:2(11Z,14Z)), and LysoPC (22:5(4Z,7Z,10Z,13Z,16Z)) were significantly increased after MCT intervention, and the concentrations of LysoPC (18:0), palmitic acid, linoleic acid, oleic acid, and 7,12-dimethylbenz[a]anthracene were significantly decreased (p < 0.05), whereas no significant changes appeared after the placebo intervention. Androstenedione concentration increased after placebo intervention. Furthermore, a significant negative correlation was observed between changes in LysoPC (P-18:1(9Z)) and ADAS-Cog-C scores after MCT intervention (r = -0.1472, p < 0.05).
Conclusions: MCT had positive effects on cognitive ability in mild to moderate AD patients with APOE4. These effects of MCT might be related to the metabolism of LysoPC, oleic acid, linoleic acid and palmitic acid, in addition to the ketogenic effect.
Study Id Number: ChiCTR-IOR-16009737.
Registry Website: WHO ICTRP Search Portal - http://apps.who.int/trialsearch/Default.aspx.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clnu.2019.10.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preliminary study of Kinesio Taping in rectus abdominis diastasis treatment and abdominal circumference improvement in postpartum women: a retrospective study.
Sci Rep
December 2024
Department of Obstetrics and Gynecology rehabilitation, West China Second Hospital, Sichuan University, Huaxi Technology Building, 16 Linjiang Middle Road, Wuhou District, Chengdu, 610000, Sichuan, China.
Rectus abdominis diastasis (RAD) is a key factor in the rehabilitation of postpartum women. This study aimed to evaluate the clinical efficacy of Kinesio Taping (KT) in RAD treatment and abdominal changes. The medical records of women with RAD who received KT treatment at the hospital were reviewed.
View Article and Find Full Text PDFImpact of COVID-19 on heart rate variability in post-COVID individuals compared to a control group.
Sci Rep
December 2024
Cardiopulmonary Physiotherapy Laboratory, Physical Therapy Department, Universidade Federal de São Carlos, Rodovia Washington Luiz, São Carlos, SP, 13565-905, Brazil.
This study investigated the impact of mild COVID-19 on HRV in groups stratified by time after infection and to compare to a healthy group of the same age without previous virus infection and without need of hospitalization. This is a cross-sectional study. We divided the sample into four groups: control group (CG) (n = 31), group 1 (G1): ≤6 weeks (n = 34), group 2 (G2): 2-6 months (n = 30), group 3 (G3): 7-12 months (n = 35) after infection.
View Article and Find Full Text PDFModified Crohn's Disease Exclusion Diet Maintains Remission in Pediatric Crohn's Disease; Randomized Controlled Trial.
Clin Gastroenterol Hepatol
December 2024
Department of Pediatrics, University of Alberta, Edmonton, AB, Canada; Department of Physiology, University of Alberta, Edmonton, AB, Canada. Electronic address:
Background & Aims: The Crohn's Disease (CD) Exclusion Diet (CDED)+Partial Enteral Nutrition (PEN) is effective for inducing remission in mild-moderate CD. We assessed whether a 2-week course of Exclusive Enteral Nutrition (EEN), followed by CDED+PEN is superior to 8 weeks of EEN in sustaining clinical remission at week 14 in mild-to-severe CD and if CDED+PEN can maintain remission to week 24.
Methods: This international, multicenter, randomized-controlled trial compared 2-weeks of EEN (Modulen®IBD) followed by 3 phases of the CDED+PEN (henceforth CDED) to 8 weeks of EEN, followed by PEN with free diet up to week 24 (henceforth EEN).
Computer model for gait assessments in Parkinson's patients using a fuzzy inference model and inertial sensors.
Artif Intell Med
December 2024
Escuela Nacional de Medicina y Homeopatía, Instituto Politécnico Nacional, Guillermo Massieu 239, 07320 Mexico City, Mexico.
Patients with Parkinson's disease (PD) in the moderate and severe stages can present several walk alterations. They can show slow movements and difficulty initiating, varying, or interrupting their gait; freezing; short steps; speed changes; shuffling; little arm swing; and festinating gait. The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) has a good reputation for uniformly evaluating motor and non-motor aspects of PD.
View Article and Find Full Text PDFSimplified Approach to Managing Newly Diagnosed Patients with Mild-to-Moderate Hypertension in Routine Clinical Practice.
Adv Ther
December 2024
Global Medical and Patient Affairs, Servier, Suresnes, France.
Introduction: The aim of the observational SIMPLE study was to assess real-life effectiveness and safety of a single-pill combination (SPC) of perindopril arginine/amlodipine in a broad range of subjects with newly diagnosed mild-to-moderate hypertension treated in Canadian general practice.
Methods: Treatment-naïve participants aged 18-65 years with mild-to-moderate hypertension, whose physicians decided to initiate the perindopril/amlodipine SPC, were recruited from Canadian clinical practice from October 2017 to February 2019. Participants were followed at 3- (M3) and 6-month (M6) visits after treatment initiation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!